Pacific Biosciences Of Stock Performance
| PACB Stock | USD 1.51 0.05 3.21% |
The company holds a Beta of 0.76, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pacific Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Pacific Biosciences is expected to be smaller as well. At this point, Pacific Biosciences has a negative expected return of -0.58%. Please make sure to check Pacific Biosciences' total risk alpha, kurtosis, and the relationship between the information ratio and potential upside , to decide if Pacific Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Pacific Biosciences of has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in April 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Cathie Wood shells out 1.3 million on biotech stock | 12/31/2025 |
2 | Pacific Biosciences of California, Inc. Receives 2.08 Consensus Target Price from Brokerages | 02/05/2026 |
3 | PacBio Earnings What To Look For From PACB | 02/11/2026 |
4 | Pacific Biosciences Q4 Earnings Snapshot | 02/12/2026 |
5 | Pacific Biosciences of California Q4 Earnings Call Highlights | 02/13/2026 |
6 | Disposition of 35215 shares by Farmer Michele of Pacific Biosciences at 1.576 subject to Rule 16b-3 | 02/17/2026 |
7 | Pacific Biosciences of California Insider Michele Farmer Sells 35,215 Shares | 02/20/2026 |
8 | Why The PacBio Narrative Is Shifting Around Fair Value And Long Read Sequencing | 02/23/2026 |
| Begin Period Cash Flow | 56.1 M | |
| Total Cashflows From Investing Activities | 115.4 M |
Pacific Biosciences Relative Risk vs. Return Landscape
If you would invest 239.00 in Pacific Biosciences of on December 5, 2025 and sell it today you would lose (83.00) from holding Pacific Biosciences of or give up 34.73% of portfolio value over 90 days. Pacific Biosciences of is currently does not generate positive expected returns and assumes 5.0274% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Pacific, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pacific Biosciences Target Price Odds to finish over Current Price
The tendency of Pacific Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.51 | 90 days | 1.51 | over 95.33 |
Based on a normal probability distribution, the odds of Pacific Biosciences to move above the current price in 90 days from now is over 95.33 (This Pacific Biosciences of probability density function shows the probability of Pacific Stock to fall within a particular range of prices over 90 days) .
Pacific Biosciences Price Density |
| Price |
Predictive Modules for Pacific Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pacific Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Pacific Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Pacific Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pacific Biosciences is not an exception. The market had few large corrections towards the Pacific Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pacific Biosciences of, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pacific Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.56 | |
β | Beta against Dow Jones | 0.76 | |
σ | Overall volatility | 0.31 | |
Ir | Information ratio | -0.11 |
Pacific Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pacific Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pacific Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pacific Biosciences generated a negative expected return over the last 90 days | |
| Pacific Biosciences has high historical volatility and very poor performance | |
| Pacific Biosciences may become a speculative penny stock | |
| Pacific Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 160 M. Net Loss for the year was (546.38 M) with profit before overhead, payroll, taxes, and interest of 54.85 M. | |
| Pacific Biosciences of currently holds about 834.34 M in cash with (111.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pacific Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Why The PacBio Narrative Is Shifting Around Fair Value And Long Read Sequencing |
Pacific Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Pacific Stock often depends not only on the future outlook of the current and potential Pacific Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pacific Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 300 M | |
| Cash And Short Term Investments | 279.5 M |
Pacific Biosciences Fundamentals Growth
Pacific Stock prices reflect investors' perceptions of the future prospects and financial health of Pacific Biosciences, and Pacific Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pacific Stock performance.
| Return On Equity | -2.13 | ||||
| Return On Asset | -0.34 | ||||
| Operating Margin | (1.35) % | ||||
| Current Valuation | 912.01 M | ||||
| Shares Outstanding | 302 M | ||||
| Price To Earning | 197.88 X | ||||
| Price To Book | 91.44 X | ||||
| Price To Sales | 2.94 X | ||||
| Revenue | 160 M | ||||
| Gross Profit | 54.85 M | ||||
| EBITDA | (34.2 M) | ||||
| Net Income | (546.38 M) | ||||
| Cash And Equivalents | 834.34 M | ||||
| Cash Per Share | 3.69 X | ||||
| Total Debt | 759.46 M | ||||
| Debt To Equity | 1.51 % | ||||
| Current Ratio | 11.19 X | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (111.21 M) | ||||
| Earnings Per Share | (1.82) X | ||||
| Market Capitalization | 471.12 M | ||||
| Total Asset | 784.08 M | ||||
| Retained Earnings | (2.15 B) | ||||
| Working Capital | 429.38 M | ||||
| Current Asset | 110.54 M | ||||
| Current Liabilities | 38.18 M | ||||
About Pacific Biosciences Performance
By analyzing Pacific Biosciences' fundamental ratios, stakeholders can gain valuable insights into Pacific Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pacific Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pacific Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 164.54 | 163.15 | |
| Return On Tangible Assets | (1.21) | (1.15) | |
| Return On Capital Employed | (0.76) | (0.80) | |
| Return On Assets | (0.70) | (0.73) | |
| Return On Equity | (102.15) | (97.04) |
Things to note about Pacific Biosciences performance evaluation
Checking the ongoing alerts about Pacific Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pacific Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pacific Biosciences generated a negative expected return over the last 90 days | |
| Pacific Biosciences has high historical volatility and very poor performance | |
| Pacific Biosciences may become a speculative penny stock | |
| Pacific Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 160 M. Net Loss for the year was (546.38 M) with profit before overhead, payroll, taxes, and interest of 54.85 M. | |
| Pacific Biosciences of currently holds about 834.34 M in cash with (111.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pacific Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Why The PacBio Narrative Is Shifting Around Fair Value And Long Read Sequencing |
- Analyzing Pacific Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pacific Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Pacific Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pacific Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pacific Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pacific Biosciences' stock. These opinions can provide insight into Pacific Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pacific Stock analysis
When running Pacific Biosciences' price analysis, check to measure Pacific Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacific Biosciences is operating at the current time. Most of Pacific Biosciences' value examination focuses on studying past and present price action to predict the probability of Pacific Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacific Biosciences' price. Additionally, you may evaluate how the addition of Pacific Biosciences to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |